Introduction
CML
CHRONIC MYELOID LEUKEMIA, CML, CMV INFECTION, HEMATOLOGICAL MALIGNANCIES
During the last two decades, tyrosine kinase inhibitors (TKIs) have drastically improved the outcome of chronic myeloid leukemia (CML) patients in chronic-phase (CP) (Given that leukemic stem cells (LSCs) persist even in patients with a complete molecular response (In the context of hematological malignancies, Cichocki et al. described the presence of a CD56Taking into account the role of the immune system, it is of great interest to characterize NK cells of patients who discontinue therapy in order to seek differences between those that can sustain a deep molecular response without therapy and those who suffer a molecular relapse. In this study, we present evidence suggesting that the presence of a subpopulation of mature NK cells with features associated to the expansion after HCMV infection and NCR expression might have a role in successful discontinuation of TKI treatment.